AU2016338916B2 - Enhancing beta cell replication and/or survival - Google Patents

Enhancing beta cell replication and/or survival Download PDF

Info

Publication number
AU2016338916B2
AU2016338916B2 AU2016338916A AU2016338916A AU2016338916B2 AU 2016338916 B2 AU2016338916 B2 AU 2016338916B2 AU 2016338916 A AU2016338916 A AU 2016338916A AU 2016338916 A AU2016338916 A AU 2016338916A AU 2016338916 B2 AU2016338916 B2 AU 2016338916B2
Authority
AU
Australia
Prior art keywords
gaba
pam
activating ligand
receptor activating
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016338916A
Other languages
English (en)
Other versions
AU2016338916A1 (en
Inventor
Daniel L. Kaufman
Jide Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2016338916A1 publication Critical patent/AU2016338916A1/en
Application granted granted Critical
Publication of AU2016338916B2 publication Critical patent/AU2016338916B2/en
Priority to AU2022202004A priority Critical patent/AU2022202004B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2016338916A 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival Active AU2016338916B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022202004A AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562241566P 2015-10-14 2015-10-14
US62/241,566 2015-10-14
US201662279908P 2016-01-18 2016-01-18
US62/279,908 2016-01-18
PCT/US2016/056528 WO2017066240A1 (en) 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022202004A Division AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Publications (2)

Publication Number Publication Date
AU2016338916A1 AU2016338916A1 (en) 2018-05-31
AU2016338916B2 true AU2016338916B2 (en) 2021-12-23

Family

ID=58518528

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016338916A Active AU2016338916B2 (en) 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival
AU2022202004A Active AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022202004A Active AU2022202004B2 (en) 2015-10-14 2022-03-23 Enhancing beta cell replication and/or survival

Country Status (7)

Country Link
US (1) US20180235916A1 (enExample)
EP (1) EP3362069A4 (enExample)
JP (2) JP6957455B2 (enExample)
KR (1) KR20180054796A (enExample)
CN (1) CN108697712A (enExample)
AU (2) AU2016338916B2 (enExample)
WO (1) WO2017066240A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2806877B2 (en) 2012-01-23 2025-01-29 Sage Therapeutics, Inc. Neuroactive steroid formulations comprising a complex of allopregnanolone and sulfobutyl ether beta-cyclodextrin
BR112015003747A2 (pt) 2012-08-21 2017-07-04 Sage Therapeutics Inc métodos de tratamento de epilepsia ou estado de mal epiléptico
EP2925327B1 (en) 2012-11-30 2024-01-10 The Regents of The University of California Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
CN113616661A (zh) 2016-03-08 2021-11-09 萨奇治疗股份有限公司 神经活性类固醇、其组合物及用途
CA3104810A1 (en) * 2017-06-23 2018-12-27 The Regents Of The University Of California Enhancing gaba's ability to modulate immune responses
EP3866777A4 (en) * 2018-10-18 2022-07-20 The Regents of the University of California COMBINATION THERAPIES FOR THE TREATMENT OF INFLAMMATORY DISEASES
CN115361944A (zh) * 2020-01-10 2022-11-18 均衡生物制药私人有限责任公司 用阿维菌素治疗神经病症
US20250375429A1 (en) * 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2014048788A1 (en) * 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
WO2015140081A1 (en) * 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012050907A2 (en) * 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2014048788A1 (en) * 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
WO2015140081A1 (en) * 2014-03-18 2015-09-24 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHWEH A Y ET AL, "Effect of GABA agonists on the neurotoxicity and anticonvulsant activity of benzodiazepines", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 36, no. 8, (1985-02-25), pages 737 - 744, (1985-02-25) *
DAVIES L P ET AL, "Substituted imidazo[1,2-b]pyridazines", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, US, vol. 44, no. 8, ISSN 0006-2952, (1992-10-20), pages 1555 - 1561, (1992-10-20) *
E S El-Denshary ET AL, "Effects of tetracycline and diazepam on insulin secretion and adenylyl cyclase activity of isolated rat islets of Langerhans.", Diabete Metab. 1977 Mar;3(1):3-6., (1977-01-01), pages 3 - 6, *
J. TIAN ET AL, "-Aminobutyric Acid Regulates Both the Survival and Replication of Human -Cells", DIABETES, US, (2013-08-30), vol. 62, no. 11, doi:10.2337/db13-0931, ISSN 0012-1797, pages 3760 - 3765 *
JIDE TIAN ET AL, "Clinically applicable GABA receptor positive allosteric modulators promote ß-cell replication", SCIENTIFIC REPORTS, (2017-03-23), vol. 7, no. 1, doi:10.1038/s41598-017-00515-y *
PAUL SM, "Alcohol-sensitive GABA receptors and alcohol antagonists", 2006-05-22, (2006-05-22) *
RAMIREZ G ET AL, "Gabaergic modulation of acetylcholine release in cholinergic synaptosomes from Torpedo marmorata electric organ", NEUROSCIENCE, NEW YORK, NY, US, vol. 30, no. 1, (1989-01-01), pages 251 - 255. *
Riitta Selkgmaa ET AL, "Photochemical decomposition of midazolam. I. Isolation and identification of products", Inrernotional Journal of Pharmaceutics, (1989-01-01), pages 83 - 89. *
Surwit et al. Psychosomatic Medicine, vol. 48, No. 3/4, March/April, 1986. (Year: 1986) *

Also Published As

Publication number Publication date
CN108697712A (zh) 2018-10-23
EP3362069A1 (en) 2018-08-22
US20180235916A1 (en) 2018-08-23
EP3362069A4 (en) 2019-10-02
JP6957455B2 (ja) 2021-11-02
AU2016338916A1 (en) 2018-05-31
AU2022202004B2 (en) 2024-09-19
JP2022008902A (ja) 2022-01-14
JP2018530581A (ja) 2018-10-18
WO2017066240A1 (en) 2017-04-20
AU2022202004A1 (en) 2022-04-14
KR20180054796A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
AU2022202004B2 (en) Enhancing beta cell replication and/or survival
Cutrer et al. Possible mechanisms of valproate in migraine prophylaxis
KR101546031B1 (ko) Ｃｍｔ 및 관련 장애를 치료하기 위한 신규 치료적 접근법
CN101080224B (zh) 治疗疼痛的组合物及其应用
AU2009259336B2 (en) Combination of pilocarpin and methimazol for treating Charcot-Marietooth disease and related disorders
US11992495B2 (en) Enhancing GABA's ability to modulate immune responses
GB2448224A (en) Combination of a nicotine receptor agonist and a dopaminergic agent with reduced side effects in the treatment of Parkinson's disease and the like
EP2892518A2 (en) New therapeutic approaches for treating parkinson's disease
US20130045988A1 (en) Combination therapy
Koltunowska et al. The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats
Rezvani et al. Sub-anesthetic doses of ketamine attenuate nicotine self-administration in rats
Wei et al. Agmatine inhibits morphine-induced locomotion sensitization and morphine-induced changes in striatal dopamine and metabolites in rats
AU2004283047B2 (en) Pharmaceutical composition comprising a selective I1 imidazoline receptor agonist and an angiotensin II receptor blocker
US10533012B2 (en) (R)-pirlindole and its pharmaceutically acceptable salts for use in medicine
CA3043292A1 (en) Enhancing beta cell replication and/or survival
Reiss et al. The nociceptin orphanin FQ peptide receptor agonist, Ro64-6198, impairs recognition memory formation through interaction with glutamatergic but not cholinergic receptor antagonists
HK1262672A1 (en) Enhancing beta cell replication and/or survival
Poshyvak et al. Axitinib displays antiseizure activity on pentylenetetrazol–induced kindling mode
EP0703781A1 (fr) Utilisation de l'efaroxan et de ses derives pour la preparation d'un medicament destine au traitement de la maladie de parkinson
CA2523331A1 (en) Combination of desoxypeganine and mecamylamine for the treatment of alcohol abuse
Liu Identification and Characterization of Antidiabetic and Antihypertensive Agents from Three Traditional Herbal Medicines
WO2025096942A1 (en) Trimeprazine for use in treating pain associated with trigeminal neuralgia
Krishna et al. A COMPREHENSIVE REVIEW ON CANDESARTAN CILEXETIL: PHARMACOLOGICAL, PHARMACEUTICAL AND ANALYTICAL PROFILE
Elhauge et al. (425) Dissolution studies in the presence of alcohol with an abuse-deterrent, extended-release morphine product candidate
Guacil Alteplase Thrombolytic Actilyse® Activase®

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)